Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 2.5% – Should You Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) traded down 2.5% during mid-day trading on Monday . The company traded as low as $19.27 and last traded at $19.30. 89,235 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 781,728 shares. The stock had previously closed at $19.79.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Piper Sandler reduced their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The firm has a fifty day simple moving average of $21.05 and a 200 day simple moving average of $22.64. The company has a market cap of $2.50 billion, a price-to-earnings ratio of -4.00 and a beta of 0.97.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the sale, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This trade represents a 7.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 12,563 shares of the firm’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17. Following the completion of the sale, the chief executive officer now owns 3,775,772 shares in the company, valued at approximately $73,967,373.48. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 45,873 shares of company stock worth $952,553 over the last 90 days. Insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ARWR. Commonwealth Equity Services LLC lifted its position in Arrowhead Pharmaceuticals by 3.7% in the second quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock worth $901,000 after purchasing an additional 1,250 shares during the period. Rhumbline Advisers lifted its position in Arrowhead Pharmaceuticals by 2.9% in the second quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock worth $9,955,000 after purchasing an additional 10,924 shares during the period. TD Asset Management Inc lifted its position in Arrowhead Pharmaceuticals by 90.8% in the second quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock worth $1,409,000 after purchasing an additional 25,800 shares during the period. Victory Capital Management Inc. lifted its position in Arrowhead Pharmaceuticals by 67.3% in the second quarter. Victory Capital Management Inc. now owns 41,090 shares of the biotechnology company’s stock worth $1,068,000 after purchasing an additional 16,534 shares during the period. Finally, Arizona State Retirement System lifted its position in Arrowhead Pharmaceuticals by 2.4% in the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock worth $901,000 after purchasing an additional 821 shares during the period. 62.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.